Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3821 Phase I in Healthy Subjects
NCT05380934Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tqh3821 in rheumatoid arthritis (RA) (8 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Adverse events (AEs). Started May 2022; status: completed.
02
Drugs
tqh3821
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05380934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380934.